Thu, 20 July 2017
For July 20, 2017. Artificial Intelligence is about to play a major role in the pharmaceutical industry. On July 2nd of this year, Glaxo-Smith-Kline revealed a 43-million dollar deal in which they will use A.I. to make the process of discovering new drugs easier. The goal is to reduce the time it takes from identifying a target for disease intervention to finding a molecule that acts against it. He hopes to bring it from an average 5 and a half years today to just one year in the very near future.
Category:general -- posted at: 11:29am MDT
Sat, 6 May 2017
Occupational Toxicology and Occupational Medicine - Where are they the same and where are they different? In this episode of the BioPharma EHS Podcast, Dean M. Calhoun, President and CEO of Affygility Solutions hosts a discussion between Dr. Mark Cunningham-Hill, President of Worldwide Health Consulting LLC and Dr. Frank Richardson, Principal Toxicologist for Affygility Solutions LLC.
The discussion starts out covering the basic elements of an occupational medicine program and the unique challenges posed by the pharmaceutical industry in which occupational exposure to potent compounds can cause adverse effects in workers. Then the discussion switch over to discussing occupational toxicology, dermal exposures to such compounds as fentanyl or nicotine, and hypersensitivity.
The discussion ends and Dean Calhoun then discusses upcoming events and happenings of importance to environmental, health and safety professionals in the life sciences industry.